Innovative Drugs At Center Of China’s 2024 Regulatory Efforts

Review Process, Pricing And Insurance On Agenda

The policies for China’s biopharma industry in 2024 centered around innovative small molecules, biologics and cell and gene therapies. Regulation changes for the industry in 2025 could be a continuation of that.

Looking back at 2024 and looking forward in 2025
China's regulations for the biopharma industry centered around innovative drugs in 2024; in 2025, it may be a continuation of that. (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Pink Sheet Perspectives